OncoMed Pharmaceuticals Inc (OMED.O) Company Profile
OncoMed Pharmaceuticals, Inc. (OncoMed) incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation; and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company’s anti-cancer therapeutics include anti-DLL4 (demcizumab, OMP-21M18), Anti-DLL4/Anti-VEGF Bispecific, and Anti-Notch2/3 (OMP-59R5), Anti-Notch1 (OMP-52M51, Anti-Fzd7, Fzd8-Fc, RSPO-LGR.
Anti-DLL4 (demcizumab, OMP-21M18) is a humanized monoclonal antibody that inhibits Delta Like Ligand 4 (DLL4) in the Notch signaling pathway. The Company has completed a single-agent Phase Ia trial in advanced solid tumor patients. The Company focuses on conducting two Phase Ib combination trials of demcizumab. Anti-DLL4/anti-VEGF bispecific is a monoclonal antibody that targets and inhibits both DLL4 and vascular endothelial growth factor ( VEGF). VEGF is the target of Avastin. Anti-Notch2/3 (OMP-59R5) is a human monoclonal antibody that targets the Notch2 and Notch3 receptors.
Anti-Notch1 OMP-52M51 is a humanized monoclonal antibody targeted to the Notch1 receptor. Anti-Fzd7 OMP-18R5 is a human monoclonal antibody identified by screening against the Frizzled7 receptor (Fzd7) that binds a conserved epitope on five Frizzled receptors and inhibits Wnt signaling. OMP-18R5 is in a Phase I single-agent trial in advanced solid tumor patients. Fzd8-Fc OMP-54F28 is a fusion protein based on a truncated form of the Frizzled8 receptor ( Fzd8). RSPO-LGR ligands signal through the LGR receptor family.
The Company utilizes several robust technologies for the discovery and optimization of its antibody and protein-! based therapeutics, including multiple proprietary technologies. Its antibody technologies include Mammalian Display Technology, Bispecific Antibody Technology, Hybridoma Technology. Mammalian Display Technology utilizes flow cytometry to isolate mammalian cells expressing antibodies on the cell surface with desired characteristics from large libraries of candidate antibodies. Bispecific Antibody Technology is used to generate its anti-DLL4/anti-VEGF antibody. Hybridoma Technology is used for isolating antibodies from mice, including multiplex single-cell screening techniques.
News about OMED
15 Safe Dividend Stocks to Buy for the Rest of 2018
In early June of this year, J.P. Morgan strategist Marko Kolanovic made a startling statement. Since March, President Donald Trump’s tough stance on fair trade practices have evaporated more than $1 trillion in market value. Such a drastic impa...Read More>>>
July Home Price Increases Continue Slowing
The S&P CoreLogic Case-Shiller national home price index rose 6% year over year in July to a non-seasonally adjusted (NSA) index of 205.35. That’s 0.2 percentage points lower than the month-over-month increase posted in June. In all U.S. ci...Read More>>>
Want A Bargain? 3 Cheap Stocks That Are About To Breakout
&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-1018983074&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1018983074/960x0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Charging Bull (or Wall Street Bull) i...Read More>>>
Eddie Lampert's Latest Sears Rescue Plan Shows the End Is Near
Over the past six months, Sears Holdings (NASDAQ:SHLD) CEO Eddie Lampert -- who is also the company's largest shareholder and largest creditor through his ESL Investments hedge fund -- has made several proposals to inject liquidity into Sears by buyi...Read More>>>
D-Street Buzz: Realty stocks plunge with Indiabulls Real Estate down 13%; Biocon hits new 52-week hi
The Indian stock market continues to trade on a positive note this Tuesday afternoon with the Nifty50 is up 14 points and is trading at 10,981 while the Sensex is trading higher by 135 points at 36,440.Nifty realty has plunged over 5 percent d...Read More>>>